Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia

Blood Reviews

Volumn 25, Issue 2, 2011, Pages 83-90

  Paganin, Maddalena ^a   Ferrando, Adolfo ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Gamma secretase inhibitors; Leukemia; NOTCH; Prognosis; T ALL; Targeted therapy

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; GAMMA SECRETASE INHIBITOR; GLUCOCORTICOID; MK 0752; NOTCH1 RECEPTOR; PF 03084014; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL TRANSFORMATION; DIARRHEA; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE MUTATION; GENE TARGETING; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; T CELL LEUKEMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; MUTATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTOR, NOTCH1;

EID: 79951516547     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2010.09.004     Document Type: Article

References (134)

1. Pui C.H., Relling M.V., Downing J.R. Acute lymphoblastic leukemia. N Engl J Med 2004, 350(15):1535-1548.
2. Barrett A.J., Horowitz M.M., Pollock B.H., Zhang M.J., Bortin M.M., Buchanan G.R., et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994, 331(19):1253-1258.
3. Biggs J.C., Horowitz M.M., Gale R.P., Ash R.C., Atkinson K., Helbig W., et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992, 80(4):1090-1093.
4. Dopfer R., Henze G., Bender-Gotze C., Ebell W., Ehninger G., Friedrich W., et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood 1991, 78(10):2780-2784.
5. Forman S.J., Schmidt G.M., Nademanee A.P., Amylon M.D., Chao N.J., Fahey J.L., et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol 1991, 9(9):1570-1574.
6. Schroeder H., Gustafsson G., Saarinen-Pihkala U.M., Glomstein A., Jonmundsson G., Nysom K., et al. Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia: a population-based case control study from the Nordic countries. Bone Marrow Transplant 1999, 23(6):555-560.
7. Marks D.I., Paietta E.M., Moorman A.V., Richards S.M., Buck G., DeWald G., et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009, 114(25):5136-5145.
8. Pui C.H., Pei D., Sandlund J.T., Ribeiro R.C., Rubnitz J.E., Raimondi S.C., et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2009, 24(2):371-382.
9. Ferrando A.A., Look A.T. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol 2000, 37(4):381-395.
10. Ferrando A.A., Neuberg D.S., Staunton J., Loh M.L., Huard C., Raimondi S.C., et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002, 1(1):75-87.
11. Soulier J., Clappier E., Cayuela J.M., Regnault A., Garcia-Peydro M., Dombret H., et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 2005, 106(1):274-286.
12. Ferrando A.A., Armstrong S.A., Neuberg D.S., Sallan S.E., Silverman L.B., Korsmeyer S.J., et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003, 102(1):262-268.
13. Hebert J., Cayuela J.M., Berkeley J., Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 1994, 84(12):4038-4044.
14. Weng A.P., Ferrando A.A., Lee W., Morris J.P.t., Silverman L.B., Sanchez-Irizarry C., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306(5694):269-271.
15. Aster J.C., Pear W.S., Blacklow S.C. Notch signaling in leukemia. Annu Rev Pathol 2008, 3:587-613.
16. Ferrando A.A. The role of NOTCH1 signaling in T-ALL. Hematol Am Soc Hematol Educ Program 2009, 353-361.
17. De Keersmaecker K., Graux C., Odero M.D., Mentens N., Somers R., Maertens J., et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 2005, 105(12):4849-4852.
18. Finger L.R., Kagan J., Christopher G., Kurtzberg J., Hershfield M.S., Nowell P.C., et al. Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma. Proc Natl Acad Sci USA 1989, 86(13):5039-5043.
19. Begley C.G., Aplan P.D., Denning S.M., Haynes B.F., Waldmann T.A., Kirsch I.R. The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci USA 1989, 86(24):10128-10132.
20. Chen Q., Cheng J.T., Tasi L.H., Schneider N., Buchanan G., Carroll A., et al. The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix-loop-helix protein. EMBO J 1990, 9(2):415-424.
21. Bernard O., Guglielmi P., Jonveaux P., Cherif D., Gisselbrecht S., Mauchauffe M., et al. Two distinct mechanisms for the SCL gene activation in the t(1;14) translocation of T-cell leukemias. Genes Chromosom Cancer 1990, 1(3):194-208.
22. Xia Y., Brown L., Yang C.Y., Tsan J.T., Siciliano M.J., Espinosa R., et al. TAL2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human T-cell leukemia. Proc Natl Acad Sci USA 1991, 88(24):11416-11420.
23. Mellentin J.D., Smith S.D., Cleary M.L. lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 1989, 58(1):77-83.
24. Wang J., Jani-Sait S.N., Escalon E.A., Carroll A.J., de Jong P.J., Kirsch I.R., et al. The t(14;21)(q11.2;q22) chromosomal translocation associated with T-cell acute lymphoblastic leukemia activates the BHLHB1 gene. Proc Natl Acad Sci USA 2000, 97(7):3497-3502.
25. McGuire E.A., Hockett R.D., Pollock K.M., Bartholdi M.F., O'Brien S.J., Korsmeyer S.J. The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg-1, a gene encoding a potential zinc finger protein. Mol Cell Biol 1989, 9(5):2124-2132.
26. Greenberg J.M., Boehm T., Sofroniew M.V., Keynes R.J., Barton S.C., Norris M.L., et al. Segmental and developmental regulation of a presumptive T-cell oncogene in the central nervous system. Nature 1990, 344(6262):158-160.
27. Boehm T., Foroni L., Kaneko Y., Perutz M.F., Rabbitts T.H. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci USA 1991, 88(10):4367-4371.
28. Royer-Pokora B., Loos U., Ludwig W.D. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 1991, 6(10):1887-1893.
29. Warren A.J., Colledge W.H., Carlton M.B., Evans M.J., Smith A.J., Rabbitts T.H. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994, 78(1):45-57.
30. Dube I.D., Kamel-Reid S., Yuan C.C., Lu M., Wu X., Corpus G., et al. A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14). Blood 1991, 78(11):2996-3003.
31. Hatano M., Roberts C.W., Minden M., Crist W.M., Korsmeyer S.J. Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science 1991, 253(5015):79-82.
32. Lu M., Gong Z.Y., Shen W.F., Ho A.D. The tcl-3 proto-oncogene altered by chromosomal translocation in T-cell leukemia codes for a homeobox protein. EMBO J 1991, 10(10):2905-2910.
33. Kennedy M.A., Gonzalez-Sarmiento R., Kees U.R., Lampert F., Dear N., Boehm T., et al. HOX11, a homeobox-containing T-cell oncogene on human chromosome 10q24. Proc Natl Acad Sci USA 1991, 88(20):8900-8904.
34. Hansen-Hagge T.E., Schafer M., Kiyoi H., Morris S.W., Whitlock J.A., Koch P., et al. Disruption of the RanBP17/Hox11L2 region by recombination with the TCRdelta locus in acute lymphoblastic leukemias with t(5;14)(q34;q11). Leukemia 2002, 16(11):2205-2212.
35. Nagel S., Kaufmann M., Drexler H.G., MacLeod R.A. The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). Cancer Res 2003, 63(17):5329-5334.
36. Przybylski G.K., Dik W.A., Grabarczyk P., Wanzeck J., Chudobska P., Jankowski K., et al. The effect of a novel recombination between the homeobox gene NKX2-5 and the TRD locus in T-cell acute lymphoblastic leukemia on activation of the NKX2-5 gene. Haematologica 2006, 91(3):317-321.
37. Speleman F., Cauwelier B., Dastugue N., Cools J., Verhasselt B., Poppe B., et al. A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia 2005, 19(3):358-366.
38. Shima E.A., Le Beau M.M., McKeithan T.W., Minowada J., Showe L.C., Mak T.W., et al. Gene encoding the alpha chain of the T-cell receptor is moved immediately downstream of c-myc in a chromosomal 8;14 translocation in a cell line from a human T-cell leukemia. Proc Natl Acad Sci USA 1986, 83(10):3439-3443.
39. Erikson J., Finger L., Sun L., ar-Rushdi A., Nishikura K., Minowada J., et al. Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias. Science 1986, 232(4752):884-886.
40. Urashima M., Iyori H., Fujisawa K., Hoshi Y., Akatsuka J., Maekawa K. Establishment and characteristics of a T-cell acute lymphoblastic leukemia cell line, JK-T1, with a chromosomal translocation between 8q24 and 14q13. Cancer Genet Cytogenet 1992, 64(1):86-90.
41. Inaba T., Murakami S., Oku N., Itoh K., Ura Y., Nakanishi S., et al. Translocation between chromosomes 8q24 and 14q11 in T-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet 1990, 49(1):69-74.
42. Shima-Rich E.A., Harden A.M., McKeithan T.W., Rowley J.D., Diaz M.O. Molecular analysis of the t(8;14)(q24;q11) chromosomal breakpoint junctions in the T-cell leukemia line MOLT-16. Genes Chromosom Cancer 1997, 20(4):363-371.
43. Clappier E., Cuccuini W., Kalota A., Crinquette A., Cayuela J.M., Dik W.A., et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 2007, 110(4):1251-1261.
44. Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D., et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66(4):649-661.
45. Palomero T., Barnes K.C., Real P.J., Bender J.L., Sulis M.L., Murty V.V., et al. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. Leukemia 2006, 20(7):1279-1287.
46. Aplan P.D., Lombardi D.P., Ginsberg A.M., Cossman J., Bertness V.L., Kirsch I.R. Disruption of the human SCL locus by "illegitimate" V-(D)-J recombinase activity. Science 1990, 250(4986):1426-1429.
47. Van Vlierberghe P., van Grotel M., Beverloo H.B., Lee C., Helgason T., Buijs-Gladdines J., et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 2006, 108(10):3520-3529.
48. Lahortiga I., De Keersmaecker K., Van Vlierberghe P., Graux C., Cauwelier B., Lambert F., et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 2007, 39(5):593-595.
49. O'Neil J., Tchinda J., Gutierrez A., Moreau L., Maser R.S., Wong K.K., et al. Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med 2007, 204(13):3059-3066.
50. Dreyling M.H., Martinez-Climent J.A., Zheng M., Mao J., Rowley J.D., Bohlander S.K. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc Natl Acad Sci USA 1996, 93(10):4804-4809.
51. Carlson K.M., Vignon C., Bohlander S., Martinez-Climent J.A., Le Beau M.M., Rowley J.D. Identification and molecular characterization of CALM/AF10fusion products in T cell acute lymphoblastic leukemia and acute myeloid leukemia. Leukemia 2000, 14(1):100-104.
52. Asnafi V., Radford-Weiss I., Dastugue N., Bayle C., Leboeuf D., Charrin C., et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood 2003, 102(3):1000-1006.
53. Chervinsky D.S., Sait S.N., Nowak N.J., Shows T.B., Aplan P.D. Complex MLL rearrangement in a patient with T-cell acute lymphoblastic leukemia. Genes Chromosom Cancer 1995, 14(1):76-84.
54. Rubnitz J.E., Behm F.G., Curcio-Brint A.M., Pinheiro R.P., Carroll A.J., Raimondi S.C., et al. Molecular analysis of t(11;19) breakpoints in childhood acute leukemias. Blood 1996, 87(11):4804-4808.
55. Van Vlierberghe P., van Grotel M., Tchinda J., Lee C., Beverloo H.B., van der Spek P.J., et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 2008, 111(9):4668-4680.
56. Hussey D.J., Nicola M., Moore S., Peters G.B., Dobrovic A. The (4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukemia. Blood 1999, 94(6):2072-2079.
57. Mecucci C., La Starza R., Negrini M., Sabbioni S., Crescenzi B., Leoni P., et al. t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia. Br J Haematol 2000, 109(4):788-793.
58. Tycko B., Smith S.D., Sklar J. Chromosomal translocations joining LCK and TCRB loci in human T cell leukemia. J Exp Med 1991, 174(4):867-873.
59. Clappier E., Cuccuini W., Cayuela J.M., Vecchione D., Baruchel A., Dombret H., et al. Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias. Leukemia 2006, 20(1):82-86.
60. Karrman K., Andersson A., Bjorgvinsdottir H., Strombeck B., Lassen C., Olofsson T., et al. Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia. Eur J Haematol 2006, 77(1):27-34.
61. Flex E., Petrangeli V., Stella L., Chiaretti S., Hornakova T., Knoops L., et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008, 205(4):751-758.
62. Graux C., Cools J., Melotte C., Quentmeier H., Ferrando A., Levine R., et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36(10):1084-1089.
63. Bar-Eli M., Ahuja H., Foti A., Cline M.J. N-RAS mutations in T-cell acute lymphocytic leukaemia: analysis by direct sequencing detects a novel mutation. Br J Haematol 1989, 72(1):36-39.
64. Kawamura M., Ohnishi H., Guo S.X., Sheng X.M., Minegishi M., Hanada R., et al. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk Res 1999, 23(2):115-126.
65. Balgobind B.V., Van Vlierberghe P., van den Ouweland A.M., Beverloo H.B., Terlouw-Kromosoeto J.N., van Wering E.R., et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 2008, 111(8):4322-4328.
66. Palomero T., Sulis M.L., Cortina M., Real P.J., Barnes K., Ciofani M., et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007, 13(10):1203-1210.
67. Tosello V., Mansour M.R., Barnes K., Paganin M., Sulis M.L., Jenkinson S., et al. WT1 mutations in T-ALL. Blood 2009, 114(5):1038-1045.
68. Kleppe M., Lahortiga I., El Chaar T., De Keersmaecker K., Mentens N., Graux C., et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet 2010, 42(6):530-535.
69. Van Vlierberghe P., Palomero T., Khiabanian H., Van der Meulen J., Castillo M., Van Roy N., et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 2010, 42(4):338-342.
70. Brou C., Logeat F., Gupta N., Bessia C., LeBail O., Doedens J.R., et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 2000, 5(2):207-216.
71. Mumm J.S., Kopan R. Notch signaling: from the outside in. Dev Biol 2000, 228(2):151-165.
72. Mumm J.S., Schroeter E.H., Saxena M.T., Griesemer A., Tian X., Pan D.J., et al. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell 2000, 5(2):197-206.
73. van Tetering G., van Diest P., Verlaan I., van der Wall E., Kopan R., Vooijs M. Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem 2009, 284(45):31018-31027.
74. Bozkulak E.C., Weinmaster G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol 2009, 29(21):5679-5695.
75. Tanigaki K., Honjo T. Regulation of lymphocyte development by Notch signaling. Nat Immunol 2007, 8(5):451-456.
76. Hozumi K., Mailhos C., Negishi N., Hirano K., Yahata T., Ando K., et al. Delta-like 4 is indispensable in thymic environment specific for T cell development. J Exp Med 2008, 205(11):2507-2513.
77. Han H., Tanigaki K., Yamamoto N., Kuroda K., Yoshimoto M., Nakahata T., et al. Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int Immunol 2002, 14(6):637-645.
78. Radtke F., Wilson A., Stark G., Bauer M., van Meerwijk J., MacDonald H.R., et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999, 10(5):547-558.
79. Pui J.C., Allman D., Xu L., DeRocco S., Karnell F.G., Bakkour S., et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 1999, 11(3):299-308.
80. Ciofani M., Zuniga-Pflucker J.C. A survival guide to early T cell development. Immunol Res 2006, 34(2):117-132.
81. Wolfer A., Wilson A., Nemir M., MacDonald H.R., Radtke F. Inactivation of Notch1 impairs VDJbeta rearrangement and allows pre-TCR-independent survival of early alpha beta Lineage Thymocytes. Immunity 2002, 16(6):869-879.
82. Reizis B., Leder P. Direct induction of T lymphocyte-specific gene expression by the mammalian Notch signaling pathway. Genes Dev 2002, 16(3):295-300.
83. Gonzalez-Garcia S., Garcia-Peydro M., Martin-Gayo E., Ballestar E., Esteller M., Bornstein R., et al. CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia. J Exp Med 2009, 206(4):779-791.
84. Weng A.P., Millholland J.M., Yashiro-Ohtani Y., Arcangeli M.L., Lau A., Wai C., et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006, 20(15):2096-2109.
85. Ciofani M., Zuniga-Pflucker J.C. Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism. Nat Immunol 2005, 6(9):881-888.
86. Pear W.S., Aster J.C., Scott M.L., Hasserjian R.P., Soffer B., Sklar J., et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996, 183(5):2283-2291.
87. Girard L., Hanna Z., Beaulieu N., Hoemann C.D., Simard C., Kozak C.A., et al. Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis. Genes Dev 1996, 10(15):1930-1944.
88. Malecki M.J., Sanchez-Irizarry C., Mitchell J.L., Histen G., Xu M.L., Aster J.C., et al. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol Cell Biol 2006, 26(12):4642-4651.
89. Sulis M.L., Williams O., Palomero T., Tosello V., Pallikuppam S., Real P.J., et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood 2008, 112(3):733-740.
90. Gordon W.R., Roy M., Vardar-Ulu D., Garfinkel M., Mansour M.R., Aster J.C., et al. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood 2009, 113(18):4381-4390.
91. Thompson B.J., Buonamici S., Sulis M.L., Palomero T., Vilimas T., Basso G., et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007, 204(8):1825-1835.
92. O'Neil J., Grim J., Strack P., Rao S., Tibbitts D., Winter C., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007, 204(8):1813-1824.
93. Akhoondi S., Sun D., von der Lehr N., Apostolidou S., Klotz K., Maljukova A., et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007, 67(19):9006-9012.
94. Minella A.C., Clurman B.E. Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle 2005, 4(10):1356-1359.
95. Fujii Y., Yada M., Nishiyama M., Kamura T., Takahashi H., Tsunematsu R., et al. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation. Cancer Sci 2006, 97(8):729-736.
96. Mao J.H., Kim I.J., Wu D., Climent J., Kang H.C., DelRosario R., et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008, 321(5895):1499-1502.
97. Chiang M.Y., Xu L., Shestova O., Histen G., L'Heureux S., Romany C., et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 2008, 118(9):3181-3194.
98. Palomero T., Lim W.K., Odom D.T., Sulis M.L., Real P.J., Margolin A., et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006, 103(48):18261-18266.
99. Margolin A.A., Palomero T., Sumazin P., Califano A., Ferrando A.A., Stolovitzky G. ChIP-on-chip significance analysis reveals large-scale binding and regulation by human transcription factor oncogenes. Proc Natl Acad Sci USA 2009, 106(1):244-249.
100. Sharma V.M., Calvo J.A., Draheim K.M., Cunningham L.A., Hermance N., Beverly L., et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol 2006, 26(21):8022-8031.
101. Chan S.M., Weng A.P., Tibshirani R., Aster J.C., Utz P.J. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007, 110(1):278-286.
102. Sade H., Krishna S., Sarin A. The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem 2004, 279(4):2937-2944.
103. Joshi I., Minter L.M., Telfer J., Demarest R.M., Capobianco A.J., Aster J.C., et al. Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood 2009, 113(8):1689-1698.
104. Dohda T., Maljukova A., Liu L., Heyman M., Grander D., Brodin D., et al. Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines. Exp Cell Res 2007, 313(14):3141-3152.
105. Rao S.S., O'Neil J., Liberator C.D., Hardwick J.S., Dai X., Zhang T., et al. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res 2009, 69(7):3060-3068.
106. Sicinska E., Aifantis I., Le Cam L., Swat W., Borowski C., Yu Q., et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 2003, 4(6):451-461.
107. Song L.L., Peng Y., Yun J., Rizzo P., Chaturvedi V., Weijzen S., et al. Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. Oncogene 2008, 27(44):5833-5844.
108. Shin H.M., Minter L.M., Cho O.H., Gottipati S., Fauq A.H., Golde T.E., et al. Notch1 augments NF-kappaB activity by facilitating its nuclear retention. EMBO J 2006, 25(1):129-138.
109. Vilimas T., Mascarenhas J., Palomero T., Mandal M., Buonamici S., Meng F., et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007, 13(1):70-77.
110. Breit S., Stanulla M., Flohr T., Schrappe M., Ludwig W.D., Tolle G., et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006, 108(4):1151-1157.
111. Park M.J., Taki T., Oda M., Watanabe T., Yumura-Yagi K., Kobayashi R., et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009, 145(2):198-206.
112. Asnafi V., Buzyn A., Le Noir S., Baleydier F., Simon A., Beldjord K., et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009, 113(17):3918-3924.
113. van Grotel M., Meijerink J.P., Beverloo H.B., Langerak A.W., Buys-Gladdines J.G., Schneider P., et al. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. Haematologica 2006, 91(9):1212-1221.
114. Mansour M.R., Sulis M.L., Duke V., Foroni L., Jenkinson S., Koo K., et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol 2009, 27(26):4352-4356.
115. Zuurbier L., Homminga IC V., te Winkel M.L., Buijs-Gladdines J., Kooi C., Smits W.K., et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell Acute Lymphoblastic Leukemia patients treated on DCOG or COALL protocols. Leukemia 2010, 24(12):2014-2022.
116. Clappier E., Collette S., Grardel N., Girard S., Suarez L., Brunie G., et al. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment but not on outcome in children with T-cell acute lymphoblastic (T-ALL) leukemia treated on EORTC trials 58881 and 58951. Leukemia 2010, 24(12):2323-2331.
117. Kox K.Z., Stanulla M., Leibe S., Schrappe M., Ludwig W.D., Koehler R., et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 2010, 24(12):2003-2004.
118. Evin G., Sernee M.F., Masters C.L. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs 2006, 20(5):351-372.
119. Selkoe D., Kopan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 2003, 26:565-597.
120. Deangelo D., Stone R., Silverman L., Stock W., Attar E., Fearen I., et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 2006, 24(18S):6585.
121. van Es J.H., van Gijn M.E., Riccio O., van den Born M., Vooijs M., Begthel H., et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435(7044):959-963.
122. Riccio O., van Gijn M.E., Bezdek A.C., Pellegrinet L., van Es J.H., Zimber-Strobl U., et al. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27(Kip1) and p57(Kip2). EMBO Rep 2008, 9(4):377-383.
123. Milano J., McKay J., Dagenais C., Foster-Brown L., Pognan F., Gadient R., et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004, 82(1):341-358.
124. Tammam J., Ware C., Efferson C., O'Neil J., Rao S., Qu X., et al. Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol 2009, 158(5):1183-1195.
125. Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 17(4):400-411.
126. Cullion K., Draheim K.M., Hermance N., Tammam J., Sharma V.M., Ware C., et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 2009, 113(24):6172-6181.
127. De Keersmaecker K., Lahortiga I., Mentens N., Folens C., Van Neste L., Bekaert S., et al. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 2008, 93(4):533-542.
128. Real P.J., Tosello V., Palomero T., Castillo M., Hernando E., de Stanchina E., et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009, 15(1):50-58.
129. Real P.J., Ferrando A.A. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia 2009, 23(8):1374-1377.
130. Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther. 9(6):1618-1628.
131. Medyouf H., Gao X., Armstrong F., Gusscott S., Liu Q., Gedman A.L., et al. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood 2010, 115(6):1175-1184.
132. Moellering R.E., Cornejo M., Davis T.N., Del Bianco C., Aster J.C., Blacklow S.C., et al. Direct inhibition of the NOTCH transcription factor complex. Nature 2009, 462(7270):182-188.
133. Wu Y., Cain-Hom C., Choy L., Hagenbeek T.J., de Leon G.P., Chen Y., et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464(7291):1052-1057.
134. Aste-Amezaga M., Zhang N., Lineberger J.E., Arnold B.A., Toner T.J., et al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One 2010, 5(2):e9094.